PCSK9 drug's Ph. III results show potent effects on lipids

Sanofi/Regeneron's highly touted PCSK9 inhibitor, alirocumab, cut LDL "bad" cholesterol by half in the ODYSSEY MONO trial. ODYSSEY MONO is the first study to report data from the 12 Phase III trials that have been initiated so far as part of the more than 23,000 patient ODYSSEY clinical trial program.

In the release, Jay Edelberg, head of the PCSK9 development and launch unit of Sanofi Group said, "We are excited with the findings from the first Phase III trial with alirocumab.  While the majority of our clinical program is investigating alirocumab in combination with lipid-lowering therapies, these monotherapy results are encouraging."
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.